✦ LIBER ✦

The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes

✍ Scribed by Apostolia Maria Tsimberidou; Elihu Estey; Sijin Wen; Sherry Pierce; Hagop Kantarjian; Maher Albitar; Razelle Kurzrock

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 163 KB
Volume: 113
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.23785

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Gemtuzumab, fludarabine, cytarabine, and

Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes

✍ Apostolia Tsimberidou; Elihu Estey; Jorge Cortes; Deborah Thomas; Stefan Faderl; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB

## Background: Gemtuzumab is used to treat patients with previously untreated or recurrent acute myelogenous leukemia (aml). the fludarabine and cytarabine (ara-c) regimen is active in these patients. resistance to gemtuzumab is associated with blast multidrug resistance (mdr). the objectives of th

The clinical significance of soluble CD8

The clinical significance of soluble CD86 levels in patients with acute myeloid leukemia and myelodysplastic syndrome

✍ Barry D. Hock; Judith L. McKenzie; William Nigel Patton; Lisa F. Haring; Ying Ya 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 108 KB 👁 2 views

## Abstract ## BACKGROUND Levels of the soluble form of CD86 (sCD86) are elevated in a proportion of patients with leukemia. Although it is a potential modulator of antitumor responses, the significance of sCD86 in patients with hematologic malignancies is unknown. ## METHODS The authors evaluat

The prognostic significance of bone marr

The prognostic significance of bone marrow levels of neurofibromatosis-1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome

✍ Di Lu; Randa Nounou; Miloslav Beran; Elihu Estey; Taghi Manshouri; Hagop Kantarj 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB 👁 1 views

## Abstract ## BACKGROUND It has been reported that point mutations of the ras gene occur frequently in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). However, the prognostic significance of ras gene mutations in patients with these disorders has been a controversial issue. Altho

Plasma vascular endothelial growth facto

Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes

✍ Alvaro Aguayo; Hagop M. Kantarjian; Elihu H. Estey; Francis J. Giles; Srdan Vers 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 95 KB

## Background: Vascular endothelial growth factor (vegf) and basic fibroblast growth factor (bfgf) are positive regulators of angiogenesis. increased levels in urine, serum, plasma, or malignant tissue have been associated with an adverse prognosis in patients with solid tumors. ## Methods: The a

A phase 1-2 study of a farnesyltransfera

A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome

✍ Elias Jabbour; Hagop Kantarjian; Farhad Ravandi; Guillermo Garcia-Manero; Zeev E 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 221 KB 👁 1 views

## Abstract ## BACKGROUND: The authors conducted a phase 1/2 study of tipifarnib in combination with idarubicin and cytarabine (IA) in 95 patients with previously untreated acute myeloid leukemia (AML) or high‐risk myelodysplastic syndrome. ## METHODS: Induction consisted of idarubicin 12 mg/m^2

Results of imatinib mesylate therapy in

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders

✍ Jorge Cortes; Francis Giles; Susan O'Brien; Deborah Thomas; Maher Albitar; Mary 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 1 views

## Abstract ## BACKGROUND Imatinib mesylate is a selective tyrosine kinase inhibitor of c‐abl, bcr/abl, c‐kit, and platelet‐derived growth factor‐receptor (PDGF‐R). c‐kit is expressed in most patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) and PDGF has been implicated